Alzamend Neuro, Inc. filed a Current Report on Form 8-K with the Securities and Exchange Commission on November 18, 2026, announcing that it will present at the annual meeting of the Society for Neuroscience. The company furnished a presentation as Exhibit 99.1, which details a study investigating the effects of its drug candidate AL001 compared to standard lithium carbonate on brain functional connectivity.
The study, conducted in healthy volunteers, utilized ultra-high-field resting-state functional magnetic resonance imaging (fMRI) to assess changes in brain networks following treatment. The research was conducted at the Massachusetts General Hospital Translational and Clinical Research Center (TCRC) and the Martinas Center. A total of six healthy participants completed baseline and two post-treatment imaging visits following a two-week dosing period.
Participants were randomized to receive either lithium carbonate or AL001. The study employed a 4S156 Parcels atlas to estimate parcel-wise functional connectivity (FC) using Pearson correlations and Fisher-z transformation. Data was preprocessed using fMRIPrep and de-noised using XCP-D.
Exploratory network-level comparisons were performed using two-sided Wilcoxon signed-rank tests with Benjamini-Hochberg false discovery rate (FDR) correction. The study concluded that while descriptive differences were observed between the modulation of AL001 and lithium carbonate on brain connectivity, no network-pair changes survived FDR correction. The report notes that findings remain preliminary due to the small sample size and warrant further investigation in a larger cohort.